US Patent No: 6,218,506

Number of patents in Portfolio can not be more than 2000

Amyloid .beta. protein (globular assembly and uses thereof)

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid .beta. peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
NORTHWESTERN UNIVERSITYEVANSTON, IL950
UNIVERSITY OF SOUTHERN CALIFORNIALOS ANGELES, CA882

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Barlow, Ann Evanston, IL 3 134
Chromy, Brett A Evanston, IL 14 235
Finch, Caleb E Altadena, CA 5 212
Klein, William L Winnetka, IL 29 467
Krafft, Grant A Glenview, IL 26 346
Lambert, Mary P Glenview, IL 21 353
Morgan, Todd Manhattan Beach, CA 9 152
Rozovsky, Irina Pasadena, CA 3 134
Wals, Pat Los Angeles, CA 3 134

Cited Art Landscape

  • No Cited Art to Display

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
8,859,628 Method for preventing, treating and diagnosing disorders of protein aggregation 0 2004
* 2010/0209,346 AMYLOID BETA(1-42) OLIGOMERS, DERIVATIVES THEREOF AND ANTIBODIES THERETO, METHODS OF PREPARATION THEREOF AND USE THEREOF 10 2009
 
IMIPLEX LLC (4)
8,993,714 Streptavidin macromolecular adaptor and complexes thereof 1 2010
* 2010/0329,930 STREPTAVIDIN MACROMOLECULAR ADAPTOR AND COMPLEXES THEREOF 1 2010
9,285,363 Method of protein nanostructure fabrication 0 2010
9,102,526 Node polypeptides for nanostructure assembly 0 2010
 
WYETH LLC (30)
7,189,819 Humanized antibodies that recognize beta amyloid peptide 47 2001
* 2003/0165,496 Humanized antibodies that recognize beta amyloid peptide 30 2001
7,582,733 Humanized antibodies that recognize beta amyloid peptide 19 2002
* 2005/0009,150 Humanized antibodies that recognize beta amyloid peptide 24 2002
7,256,273 Humanized antibodies that recognize beta amyloid peptide 58 2003
7,179,892 Humanized antibodies that recognize beta amyloid peptide 71 2003
* 2004/0082,762 Humanized antibodies that recognize beta amyloid peptide 10 2003
* 2004/0171,816 Humanized antibodies that recognize beta amyloid peptide 30 2003
* 2004/0171,815 Humanized antibodies that recognize beta amyloid peptide 36 2003
* 2005/0249,725 Humanized antibodies that recognize beta amyloid peptide 41 2004
7,871,615 Humanized antibodies that recognize beta amyloid peptide 14 2004
8,916,165 Humanized Aβ antibodies for use in improving cognition 0 2005
7,625,560 Humanized antibodies that recognize beta amyloid peptide 28 2005
* 2006/0257,396 Abeta antibodies for use in improving cognition 39 2005
* 2006/0198,851 Humanized Abeta antibodies for use in improving cognition 43 2005
* 2006/0165,682 Humanized antibodies that recognize beta amyloid peptide 34 2005
* 2006/0280,743 Humanized antibodies that recognize beta amyloid peptide 31 2006
* 2008/0050,367 Humanized antibodies that recognize beta amyloid peptide 24 2006
7,700,751 Humanized antibodies that recognize β-amyloid peptide 5 2007
8,613,920 Treatment of amyloidogenic diseases 0 2007
8,128,928 Humanized antibodies that recognize beta amyloid peptide 1 2007
* 2011/0142,823 Humanized antibodies that recognize beta amyloid peptide 0 2007
* 2008/0281,082 HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE 9 2007
* 2008/0292,625 PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY 14 2008
8,003,097 Treatment of cerebral amyloid angiopathy 1 2008
* 2009/0142,270 PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY 20 2008
8,784,810 Treatment of amyloidogenic diseases 0 2008
* 2011/0229,413 TREATMENT OF AMYLOIDOGENIC DISEASES 8 2008
* 2010/0266,505 IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS 10 2008
9,067,981 Hybrid amyloid-beta antibodies 0 2009
 
ABBVIE DEUTSCHLAND GMBH & CO. KG (3)
7,902,328 Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof 18 2004
8,895,004 Method for the treatment of amyloidoses 0 2008
9,176,150 Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof 0 2011
 
ACUMEN PHARMACEUTICALS, INC. (6)
9,006,283 Methods of modifying amyloid β oligomers using non-peptidic compounds 0 2007
8,962,677 Methods of restoring cognitive ability using non-peptidic compounds 0 2007
* 2009/0018,084 METHODS OF RESTORING COGNITIVE ABILITY USING NON-PEPTIDIC COMPOUNDS 11 2007
* 2009/0018,218 METHODS OF MODIFYING AMYLOID beta OLIGOMERS USING NON-PEPTIDIC COMPOUNDS 1 2007
* 2011/0098,309 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS 4 2008
9,217,024 ADDL receptor polypeptides, polynucleotides and host cells for recombinant production 0 2008
 
NORTHWESTERN UNIVERSITY (8)
* 2008/0306,074 Compositions Comprising Addl Receptors, Related Compositions, and Related Methods 1 2005
* 2008/0176,252 Amyloid beta-derived diffusible ligands (ADDLs), ADDL-surrogates, ADDL-binding molecules, and uses thereof 0 2005
7,811,563 Anti-addl antibodies and uses thereof 3 2005
7,780,963 Anti-ADDL antibodies and uses thereof 10 2005
* 2007/0048,312 Anti-ADDL antibodies and uses thereof 20 2006
8,128,930 Anti-ADDL antibodies and uses thereof 0 2010
8,889,138 Anti-ADDL antibodies and uses thereof 0 2010
8,383,113 Anti-ADDL antibodies and uses thereof 1 2012
 
Northwestern University & the University of Southern California (1)
* 2006/0178,302 Amyloid beta protein (globular assembly and uses thereof) 15 2005
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
* 2006/0039,906 Humanized antibodies that sequester abeta peptide 14 2005
 
Eli Lilly and Company (2)
8,066,999 PEGylated Aβ fab 0 2008
* 2010/0015,155 PEGYLATED ABETA FAB 0 2008
 
NEURALAB LIMITED (1)
* 2005/0123,544 Prevention and treatment of amyloidogenic disease 40 2004
 
APPLIED MOLECULAR EVOLUTION, INC. (4)
7,575,747 Aβ binding molecules 7 2004
* 2006/0110,388 binding molecules 16 2004
8,105,597 Aβ binding molecules 0 2009
8,623,365 Aβ binding molecules 0 2011
 
Immunas Pharma, Inc. (3)
9,090,679 Antibodies that specifically bind to A beta oligomers and use thereof 0 2010
8,858,949 Antibodies that specifically bind to a beta oligomers and use thereof 0 2010
8,613,924 Antibodies that specifically bind to A beta oligomers and use thereof 0 2010
 
MERCK SHARP & DOHME CORP. (5)
7,731,962 Anti-ADDL monoclonal antibody and use thereof 2 2006
8,105,593 Anti-ADDL monoclonal antibody and use thereof 0 2010
* 2010/0239,597 Anti-ADDL monoclonal antibody and use thereof 0 2010
8,420,093 Anti-ADDL monoclonal antibody and use thereof 0 2012
9,310,383 Antibodies, kit and method for detecting amyloid beta oligomers 0 2015
 
JANSSEN SCIENCES IRELAND UC (5)
6,913,745 Passive immunization of Alzheimer's disease 66 2000
9,051,363 Humanized antibodies that recognize beta amyloid peptide 0 2007
7,893,214 Humanized antibodies that recognize beta amyloid peptide 8 2007
* 2009/0069,544 HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE 15 2007
* 2008/0221,306 HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE 10 2007
 
BIOARCTIC NEUROSCIENCE AB (9)
8,106,164 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof 10 2005
7,700,719 Arctic β amyloid protofibril 7 2007
* 2007/0248,606 Treatment of Alzheimer's disease 16 2007
8,025,878 Protofibril selective antibodies and the use thereof 7 2007
* 2009/0258,009 PROTOFIBRIL SELECTIVE ANTIBODIES AND THE USE THEREOF 8 2007
9,034,334 Protofibril selective antibodies and the use thereof 0 2011
8,409,575 Antibodies specific for amyloid beta protofibril 2 2011
8,404,459 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof 1 2011
8,999,936 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof 0 2013
 
Cornell Research Foundation, Inc. (2)
6,815,175 Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder 22 2002
* 2004/0197,831 ANTI-AMYLOID PEPTIDE ANTIBODY BASED DIAGNOSIS AND TREATMENT OF A NEUROLOGICAL DISEASE OR DISORDER 4 2002
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (31)
7,964,192 Prevention and treatment of amyloidgenic disease 5 1999
7,588,766 Treatment of amyloidogenic disease 13 2000
7,575,880 Method of screening an antibody for activity in clearing an amyloid deposit 13 2000
6,905,686 Active immunization for treatment of alzheimer's disease 58 2000
* 2004/0219,146 Prevention and treatment of amyloidogenic disease 32 2004
* 2006/0121,038 Prevention and treatment of amyloidogenic disease 8 2004
* 2005/0158,304 Prevention and treatment of amyloidogenic disease 25 2004
* 2004/0265,301 Prevention and treatment of amyloidogenic disease 27 2004
* 2004/0247,591 Prevention and treatment of amyloidogenic disease 22 2004
* 2004/0247,590 Prevention and treatment of amyloidogenic disease 26 2004
8,535,673 Prevention and treatment of amyloidogenic disease 0 2004
8,034,339 Prevention and treatment of amyloidogenic disease 7 2004
* 2005/0249,727 Prevention and treatment of amyloidogenic disease 40 2004
* 2005/0191,292 Prevention and treatment of amyloidogenic disease 25 2004
* 2005/0019,330 Prevention and treatment of amyloidogenic disease 65 2004
* 2005/0013,815 Prevention and treatment of amyloidogenic disease 40 2004
* 2005/0196,399 Prevention and treatment of amyloidogenic disease 26 2004
6,972,127 Prevention and treatment of amyloidogenic disease 62 2004
* 2005/0255,122 Prevention and treatment of amyloidogenic disease 39 2004
6,946,135 Prevention and treatment of amyloidogenic disease 43 2004
* 2005/0163,788 Prevention and treatment of amyloidogenic disease 39 2004
* 2005/0037,026 PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE 10 2004
* 2005/0142,132 Prevention and treatment of amyloidogenic disease 42 2005
* 2005/0191,314 Prevention and treatment of amyloidogenic disease 35 2005
* 2006/0034,858 Prevention and treatment of amyloidogenic disease 37 2005
* 2006/0029,611 Prevention and treatment of amyloidogenic disease 37 2005
7,790,856 Humanized antibodies that recognize beta amyloid peptide 8 2006
* 2007/0154,480 Humanized antibodies that recognize beta amyloid peptide 28 2006
8,642,044 Prevention and treatment of amyloidogenic disease 0 2007
8,034,348 Prevention and treatment of amyloidogenic disease 2 2007
* 2008/0096,818 PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE 38 2007
 
University of Washington (9)
7,771,722 Assay method for alzheimer's disease 7 2002
* 2004/0043,418 Humanized antibodies that sequester Abeta peptide 30 2002
7,195,761 Humanized antibodies that sequester abeta peptide 82 2002
7,892,545 Humanized antibodies that sequester amyloid beta peptide 1 2008
* 2009/0238,821 HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE 1 2008
8,444,977 Assay method for Alzheimer's disease 0 2010
* 2010/0279,433 ASSAY METHOD FOR ALZHEIMER'S DISEASE 1 2010
8,591,894 Humanized antibodies that sequester amyloid beta peptide 1 2010
* 2011/0158,986 HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE 0 2010
 
ABBVIE INC. (13)
8,691,224 Anti-Aβ globulomer 5F7 antibodies 0 2006
8,497,072 Amyloid-beta globulomer antibodies 0 2006
8,263,558 Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins 0 2006
* 2009/0238,831 MONOCLONAL ANTIBODIES AND USES THEREOF 21 2006
* 2009/0191,190 Anti-ABeta Globulomer Antibodies, Antigen-Binding Moieties Thereof, Corresponding Hybridomas, Nucleic Acids, Vectors, Host Cells, Methods of Producing Said Antibodies, Compositions Comprising Said Antibodies, Uses Of Said Antibodies And Methods Of Using Said Antibodies 24 2006
8,455,626 Aβ conformer selective anti-aβ globulomer monoclonal antibodies 0 2007
* 2009/0035,307 Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES 23 2007
8,987,419 Amyloid-beta binding proteins 0 2011
8,877,190 Aβ conformer selective anti-Aβ globulomer monoclonal antibodies 0 2011
* 2011/0212,109 Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES 18 2011
9,062,101 Amyloid-beta binding proteins 0 2011
9,359,430 Abeta conformer selective anti-Abeta globulomer monoclonal antibodies 0 2013
9,394,360 Aβ conformer selective anti-Aβ globulomer monoclonal antibodies 0 2014
 
AC IMMUNE S.A. (3)
7,772,375 Monoclonal antibodies that recognize epitopes of amyloid-beta 28 2006
* 2011/0070,613 Monoclonal Antibody 8 2010
9,146,244 Polynucleotides encoding an anti-beta-amyloid monoclonal antibody 1 2011
 
KYOWA HAKKO KIRIN CO., LTD. (3)
8,333,967 Anti-Aβ oligomer humanized antibody 0 2010
8,303,954 Anti-Aβ oligomer humanized antibody 0 2010
9,181,332 Anti-A(β) oligomer humanized antibody 0 2012
 
MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (1)
8,974,768 Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates 0 2011
 
PLAXGEN INC (2)
8,932,558 Multi-subunit biological complexes for treatment of plaque-associated diseases 0 2008
* 2009/0104,121 Multi-subunit biological complexes for treatment of plaque-associated diseases 1 2008
 
Genentech, Inc. (15)
7,892,544 Humanized anti-beta-amyloid antibody 19 2007
8,124,353 Methods of treating and monitoring disease with antibodies 7 2007
* 2010/0150,906 ANTIBODIES 7 2007
8,613,923 Monoclonal antibody 4 2008
8,048,420 Monoclonal antibody 7 2008
* 2009/0155,249 HUMANIZED ANTIBODY IGG1 8 2008
* 2009/0017,041 Monoclonal antibody 10 2008
* 2009/0017,040 Monoclonal antibody 10 2008
9,403,902 Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody 0 2008
* 2010/0297,012 HUMANIZED ANTIBODY 8 2008
* 2010/0291,097 MONOCLONAL ANTIBODY 8 2008
8,246,954 Methods of treating amyloidosis with humanized anti-beta-amyloid antibodies 7 2009
9,221,900 Methods for identifying safe and functional humanized antibodies 0 2011
8,796,439 Nucleic acid molecules encoding a humanized antibody 4 2012
9,175,094 Monoclonal antibody 1 2013
 
NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (6)
8,378,081 Antibodies that specifically bind to Aβ oligomers and uses thereof 6 2009
* 2010/0291,071 Antibody Specific Binding to A-Beta Oligomer and the Use 6 2009
* 2010/0028,357 Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof 13 2009
* 2011/0097,319 Antibody Capable of Binding Specifically to AB-Oligomer, and Use Thereof 6 2010
9,085,614 Antibodies that specifically bind to Aβ oligomers and uses thereof 0 2012
9,090,680 Antibodies that specifically bind to abeta oligomers and uses thereof 0 2013
 
UNIVERSITY OF SOUTHERN CALIFORNIA (1)
7,638,283 Amyloid β protein (globular assembly and uses thereof) 6 2005
* Cited By Examiner